Christopher A. Carter
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research top 5%
- Cancer, Lipids, and Metabolism
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Cancer, Lipids, and Metabolism 3
- Carcinogens and Genotoxicity Assessment 2
- Cancer, Hypoxia, and Metabolism 2
- Oncology 4
- Co-authors
- Mark LynchScott M. WilhelmMargot M. IpJacques DumasLila AdnaneGunnar SchützDieter ZopfKarl‐Heinz Thierauch
- Journals
- Carcinogenesis (3 papers)Cancer Chemotherapy and Pharmacology (2 papers)Molecular Cancer Therapeutics (1 paper)Journal of Pharmacology and Experimental Therapeutics (1 paper)Investigational New Drugs (1 paper)
- Partner nations
- United StatesGermanyCanada
In The Last Decade
Christopher A. Carter
15 papers receiving 2.3k citations
Hit Papers
Peers
Comparison fields: 5 of 94
- Hepatology 512
- Cancer Research 502
- Oncology 804
- Pathology and Forensic Medicine 415
- Gastroenterology 97
Countries citing papers authored by Christopher A. Carter
This map shows the geographic impact of Christopher A. Carter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher A. Carter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher A. Carter more than expected).
Fields of papers citing papers by Christopher A. Carter
This network shows the impact of papers produced by Christopher A. Carter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher A. Carter. The network helps show where Christopher A. Carter may publish in the future.
Co-authors
The 25 scholars most cited alongside Christopher A. Carter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Hit paper breakdown → | 2010 | 1025 |
| 2 | 2006 | 70 | |
| 3 | 2006 | 388 | |
| 4 | 2006 | 85 | |
| 5 | 2005 | 228 | |
| 6 | 2001 | 3 | |
| 7 | 2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts. | 1997 | 19 |
| 8 | 1991 | 2 | |
| 9 | 1991 | 36 | |
| 10 | Release of 7-alkylguanines from N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea-modified DNA by 3-methyladenine DNA glycosylase II. | 1991 | 21 |
| 11 | 1990 | 6 | |
| 12 | 1989 | 51 | |
| 13 | 1988 | 15 | |
| 14 | Requirement of essential fatty acid for mammary tumorigenesis in the rat. | 1985 | 244 |
| 15 | Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz(a)anthracene-induced mammary tumorigenesis in rats fed different levels of fat. | 1983 | 160 |
About Christopher A. Carter
Christopher A. Carter is a scholar working on Cancer Research, Oncology, Molecular Biology, Pharmacology and Genetics, having authored 15 papers that have together received 2.4k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (4 papers), Cancer, Lipids, and Metabolism (3 papers), DNA and Nucleic Acid Chemistry (3 papers), Synthesis and biological activity (2 papers), Carcinogens and Genotoxicity Assessment (2 papers), Cancer, Hypoxia, and Metabolism (2 papers), Epigenetics and DNA Methylation (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). The work is most often cited by research in Hepatology (512 citations), Cancer Research (502 citations), Oncology (804 citations), Pathology and Forensic Medicine (415 citations) and Gastroenterology (97 citations). Christopher A. Carter has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Mark Lynch, Scott M. Wilhelm, Margot M. Ip, Jacques Dumas, Lila Adnane, Gunnar Schütz, Dieter Zopf, Karl‐Heinz Thierauch, Clement Ip and Chunrong Yu. Their work appears in journals such as Carcinogenesis, Cancer Chemotherapy and Pharmacology, Molecular Cancer Therapeutics, Journal of Pharmacology and Experimental Therapeutics and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.